Monoclonal antibodies

Multiple Myeloma Market Insight, Epidemiology and Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Pharmaceutical, Multiple myeloma, Orphan drugs, Drugs, Health care, Health sciences, Monoclonal antibodies, Breakthrough therapy

The "Multiple Myeloma- Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Myeloma- Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Multiple Myeloma epidemiology division provide the insights about historical and current Multiple Myeloma patient pool and forecasted trend for each eight major countries.
  • The Multiple Myeloma epidemiology data are studied through Multiple Myeloma possible division to give a better understanding of the Disease scenario in the 8MM.
  • The disease epidemiology covered in the report provides historical as well as forecasted Multiple Myeloma epidemiology [segmented as Total Incidence of Multiple Myeloma, Total Symptomatic Cases of Multiple Myeloma, Total Incident Cases of Multiple Myeloma Segmented by Gender, Total Diagnosed cases of Multiple Myeloma by Age Distribution, Total Cases of Multiple Myeloma by Line of Treatment] scenario of Multiple Myeloma in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030
    Drug chapter segment of the Multiple Myeloma report encloses the detailed analysis of Multiple Myeloma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777

Retrieved on: 
Tuesday, July 6, 2021
Life sciences, Immune system, Medical specialties, Branches of biology, Bristol-Myers Squibb, Bristol Myers Squibb, Agenus, Cancer immunotherapy, Monoclonal antibodies, Natural killer cell, Squib, Compugen

AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.

Key Points: 
  • AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.
  • Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology for high priority tumor indications including non-small cell lung cancer.
  • Under the terms of the agreement with Bristol Myers Squibb, Agenus receives a $200 million upfront payment in connection with the closing.
  • Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide.

Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma

Retrieved on: 
Tuesday, July 6, 2021
Research, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Health care, Health sciences, Orphan drugs, Multiple myeloma, Companies, Sanofi, Breakthrough therapy, Monoclonal antibodies, Protein domains

The GPRC5D binding domain was discovered using Eurekas proprietary E-ALPHA antibody discovery platform and developed under a collaboration agreement between Eureka and MSK.

Key Points: 
  • The GPRC5D binding domain was discovered using Eurekas proprietary E-ALPHA antibody discovery platform and developed under a collaboration agreement between Eureka and MSK.
  • GPRC5D is a novel target that has emerged as a promising option for the treatment of multiple myeloma, particularly for patients who have relapsed from other therapies, said Dr. Eric L. Smith, myeloma physician-scientist and an inventor on the patents.
  • We are delighted to contribute technology for the development of next generation therapies against multiple myeloma, said Dr. Cheng Liu, President and Chief Executive Officer of Eureka Therapeutics.
  • Under the terms of the agreement, Sanofi has exclusive rights to the GPRC5D binder for non-CAR use.

Alvotech Initiates Clinical Studies for AVT04, a Proposed Biosimilar to Stelara® (Ustekinumab)

Retrieved on: 
Tuesday, July 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Drugs, Life sciences, Biotechnology, Articles, Biosimilar, Immunosuppressants, Monoclonal antibodies, TNF inhibitors, Adalimumab, Alvotech, AVT04 and AVT02, ALVOTECH, AVT04 AND AVT02

Alvotech, the Iceland-based biosimilar company, today announced that the first patient has been dosed in the comparative, confirmatory efficacy and safety clinical study (AVT04-GL-301) for AVT04, Alvotechs proposed biosimilar to the reference product Stelara.

Key Points: 
  • Alvotech, the Iceland-based biosimilar company, today announced that the first patient has been dosed in the comparative, confirmatory efficacy and safety clinical study (AVT04-GL-301) for AVT04, Alvotechs proposed biosimilar to the reference product Stelara.
  • In parallel, Alvotech is also conducting a PK similarity study (AVT04-GL-101) to demonstrate equivalent PK endpoints between the proposed biosimilar and the reference product Stelara.
  • AVT04 is the second proposed biosimilar product from Alvotech entering clinical studies, the first being AVT02, a proposed biosimilar to Humira.
  • Rbert Wessman, founder and Chairman of Alvotech, commented:
    As a founder, I am extremely proud to see us enter the second proposed biosimilar product into clinical trials.

Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity

Retrieved on: 
Thursday, July 1, 2021
Regeneron Pharmaceuticals, Monoclonal antibodies, Life sciences, Biotechnology, Industry economics)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that scientists from the Regeneron Genetics Center(RGC) have discovered rare genetic mutations in the GPR75 gene associated with protection against obesity.

Key Points: 
  • Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that scientists from the Regeneron Genetics Center(RGC) have discovered rare genetic mutations in the GPR75 gene associated with protection against obesity.
  • "The discovery of GPR75 is already enabling Regeneron and our collaborators to identify potential ways to safely replicate the effect of this mutation through novel therapeutic approaches," said Aris Baras, M.D., Senior Vice President at Regeneron and Head of the Regeneron Genetics Center.
  • "This is the latest in a long line of protective human genetics discoveries that have fueled new therapeutics programs at Regeneron.
  • The Regeneron Genetics Center LLC (RGC) is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that focuses on early gene discovery and functional genomics.

Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today

Retrieved on: 
Wednesday, June 30, 2021
Medical specialties, Immunology, Clinical medicine, Monoclonal antibodies, Medicine, Anti-CD3 monoclonal antibody, Foralumab, Antibody

In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohns Disease.

Key Points: 
  • In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohns Disease.
  • Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical development in the world.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Baysient Launches Digital TDM App for Fast, Personalized Infliximab Dosing

Retrieved on: 
Tuesday, June 29, 2021
Medical specialties, Drugs, Clinical medicine, Monoclonal antibodies, Janssen Pharmaceutica, Biotechnology, Immune system, Immunology, Infliximab

FORT MYERS, Fla., June 29, 2021 /PRNewswire/ -- Baysient LLC announces the release of T 3 Time To Target ,a new web-based application specifically for simple precision dosing of Infliximab.

Key Points: 
  • FORT MYERS, Fla., June 29, 2021 /PRNewswire/ -- Baysient LLC announces the release of T 3 Time To Target ,a new web-based application specifically for simple precision dosing of Infliximab.
  • "This new app can be a game-changer for caregivers along the entire spectrum of IBD," noted Dr. Diane Mould, Founder and Chief Technical Officer of Baysient LLC.
  • And, it can be a nightmare in clinical trial settings when switching from Infliximab to another monoclonal antibody.
  • About Baysient: Built to provide individualized treatments for patients with improved outcomes, Baysient LLC develops SaaS, cloud-based software that provides medical providers with a full line of individual dosage-determination products.

Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors

Retrieved on: 
Tuesday, June 29, 2021
MHC class I polypeptide–related sequence B, Monoclonal antibodies

The trial design also includes a module to evaluate the safety, tolerability and anti-tumor activity of CLN-619 in combination with checkpoint inhibitor therapy.

Key Points: 
  • The trial design also includes a module to evaluate the safety, tolerability and anti-tumor activity of CLN-619 in combination with checkpoint inhibitor therapy.
  • CLN-619 is a humanized IgG1 monoclonal antibody that binds to MICA and MICB expressed on a wide variety of cancer cells.
  • This press release contains forward-looking statements of Cullinan Oncology, Inc. (Cullinan, we or our) within the meaning of the Private Securities Litigation Reform Act of 1995.
  • Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy

Retrieved on: 
Tuesday, June 29, 2021
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Infectious diseases, Clinical trials, Drugs, Clinical medicine, Cancer treatments, Bristol-Myers Squibb, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Monoclonal antibodies, Ipilimumab, Nivolumab, Bristol Myers Squibb, Melanoma

Bristol Myers Squibb (NYSE: BMY) announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) after prior fluoropyrimidine-based combination chemotherapy.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) after prior fluoropyrimidine-based combination chemotherapy.
  • Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.
  • OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • OPDIVO (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, June 29, 2021
Drugs, Lung cancer, Health sciences, Health, Breakthrough therapy, Orphan drugs, Non-small-cell lung carcinoma, Monoclonal antibodies, Treatment of lung cancer, Atezolizumab

The initial clinical results are available in a slide presentation on the Iovance website here .

Key Points: 
  • The initial clinical results are available in a slide presentation on the Iovance website here .
  • Iovance anticipates presenting additional Cohort 3B data at a medical meeting in the second half of 2021.
  • Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance, stated, There remains a very significant unmet need to increase response rates and prolong survival in the second line non-small cell lung cancer treatment setting.
  • In addition, the companys TIL cell therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC).